Cargando…

Application of Adoptive T-Cell Therapy Using Tumor Antigen-Specific T-Cell Receptor Gene Transfer for the Treatment of Human Leukemia

The last decade has seen great strides in the field of cancer immunotherapy, especially the treatment of melanoma. Beginning with the identification of cancer antigens, followed by the clinical application of anti-cancer peptide vaccination, it has now been proven that adoptive T-cell therapy (ACT)...

Descripción completa

Detalles Bibliográficos
Autores principales: Ochi, Toshiki, Fujiwara, Hiroshi, Yasukawa, Masaki
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864513/
https://www.ncbi.nlm.nih.gov/pubmed/20454585
http://dx.doi.org/10.1155/2010/521248
_version_ 1782180784886513664
author Ochi, Toshiki
Fujiwara, Hiroshi
Yasukawa, Masaki
author_facet Ochi, Toshiki
Fujiwara, Hiroshi
Yasukawa, Masaki
author_sort Ochi, Toshiki
collection PubMed
description The last decade has seen great strides in the field of cancer immunotherapy, especially the treatment of melanoma. Beginning with the identification of cancer antigens, followed by the clinical application of anti-cancer peptide vaccination, it has now been proven that adoptive T-cell therapy (ACT) using cancer antigen-specific T cells is the most effective option. Despite the apparent clinical efficacy of ACT, the timely preparation of a sufficient number of cancer antigen-specific T cells for each patient has been recognized as its biggest limitation. Currently, therefore, attention is being focused on ACT with engineered T cells produced using cancer antigen-specific T-cell receptor (TCR) gene transfer. With regard to human leukemia, ACT using engineered T cells bearing the leukemia antigen-specific TCR gene still remains in its infancy. However, several reports have provided preclinical data on TCR gene transfer using Wilms' tumor gene product 1 (WT1), and also preclinical and clinical data on TCR gene transfer involving minor histocompatibility antigen, both of which have been suggested to provide additional clinical benefit. In this review, we examine the current status of anti-leukemia ACT with engineered T cells carrying the leukemia antigen-specific TCR gene, and discuss the existing barriers to progress in this area.
format Text
id pubmed-2864513
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-28645132010-05-07 Application of Adoptive T-Cell Therapy Using Tumor Antigen-Specific T-Cell Receptor Gene Transfer for the Treatment of Human Leukemia Ochi, Toshiki Fujiwara, Hiroshi Yasukawa, Masaki J Biomed Biotechnol Review Article The last decade has seen great strides in the field of cancer immunotherapy, especially the treatment of melanoma. Beginning with the identification of cancer antigens, followed by the clinical application of anti-cancer peptide vaccination, it has now been proven that adoptive T-cell therapy (ACT) using cancer antigen-specific T cells is the most effective option. Despite the apparent clinical efficacy of ACT, the timely preparation of a sufficient number of cancer antigen-specific T cells for each patient has been recognized as its biggest limitation. Currently, therefore, attention is being focused on ACT with engineered T cells produced using cancer antigen-specific T-cell receptor (TCR) gene transfer. With regard to human leukemia, ACT using engineered T cells bearing the leukemia antigen-specific TCR gene still remains in its infancy. However, several reports have provided preclinical data on TCR gene transfer using Wilms' tumor gene product 1 (WT1), and also preclinical and clinical data on TCR gene transfer involving minor histocompatibility antigen, both of which have been suggested to provide additional clinical benefit. In this review, we examine the current status of anti-leukemia ACT with engineered T cells carrying the leukemia antigen-specific TCR gene, and discuss the existing barriers to progress in this area. Hindawi Publishing Corporation 2010 2010-05-05 /pmc/articles/PMC2864513/ /pubmed/20454585 http://dx.doi.org/10.1155/2010/521248 Text en Copyright © 2010 Toshiki Ochi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Ochi, Toshiki
Fujiwara, Hiroshi
Yasukawa, Masaki
Application of Adoptive T-Cell Therapy Using Tumor Antigen-Specific T-Cell Receptor Gene Transfer for the Treatment of Human Leukemia
title Application of Adoptive T-Cell Therapy Using Tumor Antigen-Specific T-Cell Receptor Gene Transfer for the Treatment of Human Leukemia
title_full Application of Adoptive T-Cell Therapy Using Tumor Antigen-Specific T-Cell Receptor Gene Transfer for the Treatment of Human Leukemia
title_fullStr Application of Adoptive T-Cell Therapy Using Tumor Antigen-Specific T-Cell Receptor Gene Transfer for the Treatment of Human Leukemia
title_full_unstemmed Application of Adoptive T-Cell Therapy Using Tumor Antigen-Specific T-Cell Receptor Gene Transfer for the Treatment of Human Leukemia
title_short Application of Adoptive T-Cell Therapy Using Tumor Antigen-Specific T-Cell Receptor Gene Transfer for the Treatment of Human Leukemia
title_sort application of adoptive t-cell therapy using tumor antigen-specific t-cell receptor gene transfer for the treatment of human leukemia
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864513/
https://www.ncbi.nlm.nih.gov/pubmed/20454585
http://dx.doi.org/10.1155/2010/521248
work_keys_str_mv AT ochitoshiki applicationofadoptivetcelltherapyusingtumorantigenspecifictcellreceptorgenetransferforthetreatmentofhumanleukemia
AT fujiwarahiroshi applicationofadoptivetcelltherapyusingtumorantigenspecifictcellreceptorgenetransferforthetreatmentofhumanleukemia
AT yasukawamasaki applicationofadoptivetcelltherapyusingtumorantigenspecifictcellreceptorgenetransferforthetreatmentofhumanleukemia